LivaNova PLC , a market-leading medical technology company, today reported results for the quarter and full year ended December 31, 2023 and issued guidance for 2024.
Financial Summary and.
LivaNova Reports Third-Quarter 2023 Results lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Intranasal esketamine (Spravato, Janssen) is superior to extended-release quetiapine (Seroquel, AstraZeneca) for treatment-resistant depression, results of a multicenter, head-to-head phase 3 trial show.